Fiche société
Joshua Woolley, MD, PhD
Traitements, essais et publications liés.
Traitements2programmes
Essais2liés
Publications2liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Psilocybin therapyThe purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease. | Parkinson | Phase 2 | À vérifier | United States | À vérifier |
| Psilocybin therapyThe purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease. | Parkinson | Phase 2 | À vérifier | United States | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Psilocybin therapy | Parkinson | Phase 2 | NCT04932434 | PDP1 — Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease | COMPLETED |
| Psilocybin | Parkinson | Phase 2 | NCT06455293 | PDP2 — Psilocybin Therapy for Depression in Parkinson's Disease | RECRUITING |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Psilocybin therapy | Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study. | Psychedelic medicine (New Rochelle, N.Y.) | ||
| Psilocybin therapy | A response to the letter to editor: Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy. | Journal of affective disorders |